Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYL003
- Development stage
- Preclinical
- Lead developer
- AFT Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
HYL003 (also known as LTI-201) is a stable, aqueous ophthalmic formulation of the glycopeptide antibiotic vancomycin, currently under development by AFT Pharmaceuticals and Hyloris Pharmaceuticals in partnership with Latitude Pharmaceuticals. The drug is specifically designed to treat resistant ocular infections, including those caused by Methicillin-resistant Staphylococcus aureus (MRSA), such as bacterial conjunctivitis and keratitis. Unlike traditional vancomycin eye drops, which are typically prepared extemporaneously and suffer from poor stability, HYL003 utilizes a proprietary formulation technology that allows it to remain stable at room temperature. The program is currently in the IND-enabling phase, with a pre-IND application already filed with the FDA.
- Other names
- MRSA-targeting ocular antibioticAntibiotic Eyedrop
02
Targets
D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on HYL003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYL003.